Jinyao Pharmaceuticals Receives FDA Approval for Deflazacort API

MT Newswires Live

2024/09/12

Jinyao Pharmaceutical (SHA:600488) has obtained a DMF or drug master files letter from the US Food and Drug Administration for its Deflazacort API, according to a Wednesday filing on the Shanghai Stock Exchange.

Deflazacort is an active pharmaceutical ingredient widely used to treat Duchenne muscular dystrophy. The global market for Deflazacort preparations is estimated to have reached $106 million in 2023, Jinyao said.

The FDA's approval of Jinyao Pharmaceuticals' DMF indicates that the company's Deflazacort API meets the quality standards required for use in the US.

Price (RMB): Â¥3.78, Change: Â¥-0.020, Percent Change: -0.53%

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2466214425"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2466214425\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2466214425?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-09-12 12:48","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2466214425","market":"nz","top_or_hot":-1,"title":"Jinyao Pharmaceuticals Receives FDA Approval for Deflazacort API","media":"MT Newswires Live","content":"<html><body><p>Jinyao Pharmaceuticals Receives FDA Approval for Deflazacort API</p><p> Jinyao Pharmaceutical (SHA:600488) has obtained a DMF or drug master files letter from the US Food and Drug Administration for its Deflazacort API, according to a Wednesday filing on the Shanghai Stock Exchange.</p><p>Deflazacort is an active pharmaceutical ingredient widely used to treat Duchenne muscular dystrophy. The global market for Deflazacort preparations is estimated to have reached $106 million in 2023, Jinyao said.</p><p>The FDA's approval of Jinyao Pharmaceuticals' DMF indicates that the company's Deflazacort API meets the quality standards required for use in the US.</p><p>Price (RMB): Â¥3.78, Change: Â¥-0.020, Percent Change: -0.53%</p></body></html>","source":"mtnewswires_live","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Jinyao Pharmaceuticals Receives FDA Approval for Deflazacort API</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nJinyao Pharmaceuticals Receives FDA Approval for Deflazacort API\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">MT Newswires Live</strong><span class=\"h-time small\">2024-09-12 12:48</span>\n</p>\n</h4>\n</header>\n<article>\n<html><body><p>Jinyao Pharmaceuticals Receives FDA Approval for Deflazacort API</p><p> Jinyao Pharmaceutical (SHA:600488) has obtained a DMF or drug master files letter from the US Food and Drug Administration for its Deflazacort API, according to a Wednesday filing on the Shanghai Stock Exchange.</p><p>Deflazacort is an active pharmaceutical ingredient widely used to treat Duchenne muscular dystrophy. The global market for Deflazacort preparations is estimated to have reached $106 million in 2023, Jinyao said.</p><p>The FDA's approval of Jinyao Pharmaceuticals' DMF indicates that the company's Deflazacort API meets the quality standards required for use in the US.</p><p>Price (RMB): Â¥3.78, Change: Â¥-0.020, Percent Change: -0.53%</p></body></html>\n<div class=\"bt-text\">\n\n\n<p> 來源：<a href=\"https://www.mtnewswires.com/\">MT Newswires Live</a></p>\n<p>為提升您的閱讀體驗，我們對本頁面進行了排版優化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK6100","symbol_name":"保健護理服務","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2466214425","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2466214425","pubTimestamp":1726116519,"columns":[],"sourceInfo":{"source_id":"mtnewswires_live","name":"MT Newswires Live"},"weMediaInfo":null,"summary":"Jinyao Pharmaceuticals Receives FDA Approval for Deflazacort API Jinyao Pharmaceutical (SHA:600488) ","collect":0,"end_time":0,"defaultTopTitle":"mtnewswires.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"600488":"津药药业","BK6100":"保健护理服务","BK0102":"重组","BK0012":"证金概念","BK6520":"工商业服务概念","DMF":"Dreyfus Municipal Income Inc","BK0028":"国家队","BK0239":"医药制造","OTX.SI":"迈怡汇有限公司"},"translate_title":"金耀药业Deflazacort原料药获FDA批准","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"600488":1,"DMF":1,"OTX.SI":1},"content_text":"Jinyao Pharmaceuticals Receives FDA Approval for Deflazacort API Jinyao Pharmaceutical (SHA:600488) has obtained a DMF or drug master files letter from the US Food and Drug Administration for its Deflazacort API, according to a Wednesday filing on the Shanghai Stock Exchange.Deflazacort is an active pharmaceutical ingredient widely used to treat Duchenne muscular dystrophy. The global market for Deflazacort preparations is estimated to have reached $106 million in 2023, Jinyao said.The FDA's approval of Jinyao Pharmaceuticals' DMF indicates that the company's Deflazacort API meets the quality standards required for use in the US.Price (RMB): Â¥3.78, Change: Â¥-0.020, Percent Change: -0.53%","kind":"live","is_publish_news":false,"is_publish_highlight":false,"is_publish_live":true,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}